Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial

AIMS: Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO‐DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Amod, Aslam, Marre, Michel, Joseph, Amer, Lage, Andrea, Scott, Charlie, Bakris, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293162/
https://www.ncbi.nlm.nih.gov/pubmed/34580995
http://dx.doi.org/10.1111/dom.14558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293162/
https://www.ncbi.nlm.nih.gov/pubmed/34580995
http://dx.doi.org/10.1111/dom.14558

Ejemplares similares